Sign up Australia
Proactive Investors - Run By Investors For Investors

Alcidion Group takes e-health technology to ASX listing

Alcidion Group takes e-health technology to ASX listing

E-health provider Alcidion Group (ASX:ALC) has begun trading on the ASX boards today from the reverse takeover of the shell of Naracoota Resources, which last traded at $0.056 in December.

Alcidion has built an electronic software technology that centralises patient health data, including hospital pathology and oncology records onto mobile devices.

This consolidates clinical and patient data from multiple sources across hospitals into a single platform providing benefits to clinicians as well as better patient care to avoid medical errors.

The company earned $5 million in revenues in FY15 from deployment of the platform onto beta sites. It is already deployed at Western Health, Northern Territory Health, Tasmania Health and the Royal Melbourne.

Alcidion was founded by the former chairman and CEO of the South Australian Health Commission Ray Blight and Professor Malcolm Pradhan, and are looking to rapidly scale up its U.S. presence to take advantage of looming opportunities for health tech companies.

Well known technology entrepreneur Nathan Buzza is executive director of Alcidion. He was second-largest shareholder of listed clinical tech provider Azure Healthcare.

The shares were trading ahead on re-listing.

 

Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.



Register here to be notified of future ALC Company articles
View full ALC profile

Alcidion Group Timeline

Newswire
December 21 2015

Related Articles

picture of pregnant woman
February 07 2017
MyLotus has been developed for women who have been trying to conceive for six months or more.
Harley Street London street sign
May 27 2016
The cancer treatment specialist has received funding to bring its breakthrough therapy to London.
1-Operation.jpg
January 19 2017
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.